NCT01875380已完成2 期
A Phase II Study of Single-agent Regorafenib in the First Line Treatment of Frail and/or Unfit for Polychemotherapy Patients With Metastatic Colorectal Cancer (mCRC)
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2013年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Progression-free survival rate at 6 months
研究概览
简要总结
The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signing of the informed consent form.
- •The patient must be able to understand the information and state expressly his or her desire to take part in the study.
- •Age > 18 years.
- •Patients with histologically or cytologically documented adenocarcinoma of the colon or rectum who have not been previously treated systemically for advanced disease. Patients can have received fluoropyrimidine-based adjuvant therapy if the last dose was taken at least 6 months prior to study entry.
- •Patients who are frail and/or unfit for polychemotherapy owing to the presence of one or more of the following criteria:
- •Patients with dependence in activities of daily living owing to the presence of comorbidities other than those resulting from the deterioration caused by the neoplastic disease.
- •Presence in the patient's medical history of three or more of the following comorbidities, even if they are under control with proper treatment:
- •Congestive heart failure
- •Other chronic cardiovascular diseases
- •Chronic obstructive pulmonary disease
- •Cerebrovascular disease
- •Peripheral neuropathy
- •Chronic kidney failure
- •Hypertension
- •Diabetes mellitus
- •Systemic vasculitis
- •Severe arthritis
- •Presence of geriatric syndromes such as age > 85 years, faecal or urinary incontinence, spontaneous bone fractures, mild and moderate dementia, or patients who fall repeatedly.
- •Existence of at least one measurable unidimensional lesion using CT or MRI based on the Response Evaluation Criteria in Solid Tumors criteria (RECIST), version 1.1
- •Overall Eastern Cooperative Oncology Group (ECOG) performance less than or equal to 2
- •Patient's commitment to compliance with the oral medication throughout the duration of the study
- •Life expectancy of at least 3 months
- •Adequate bone marrow, renal and hepatic function, defined as:
- •Neutrophils > 1500/mm3
- •Platelets > 100,000/mm3
- •Creatinine clearance > 30 ml/min
- •Hemoglobin ≥ 9 gr/dl
- •Bilirubin levels < 2.5 x ULN
- •Aspartate aminotransferase (AST) and alanine transaminase (ALT) levels < 3 x ULN (if liver metastases < 5 x ULN)
排除标准
- •Prior treatment with regorafenib.
- •Assignment prior to treatment during this study. Patients who are permanently withdrawn from participation in the study treatment will not be allowed to return to it.
- •Prior or concurrent presence of another neoplastic disease that is different in terms of tumour site and histology of the colorectal cancer in the 5 years prior to the inclusion of the patient in the study, except in situ cervical cancer, superficial bladder carcinoma [Ta (non-invasive), Tis (carcinoma in situ) and T1 (tumour invades lamina propria)] and non-melanoma skin tumours.
- •Presence or history of brain metastases or meningeal tumours.
- •Major surgery, open biopsy or traumatic injury within 28 days prior to the start of patient treatment with the study medication.
- •Extended-field radiotherapy within 4 weeks prior to randomisation or limited-field radiotherapy in the previous 2 weeks. Patients must have recovered from all treatment-related toxicities.
- •Pregnant or breastfeeding women. Women of childbearing age must use adequate contraception. Women of childbearing age must have a negative pregnancy test within 7 days prior to starting with the study medication.
- •Women of childbearing age and men who wish to take part in the study must agree to use adequate contraception from the signing of the informed consent until at least 3 months after stopping the study medication. The investigator or the person designated by him or her will ensure and advise as to the contraceptive methods that should be used. Appropriate contraceptive methods include abstinence, oral contraceptives, transdermal patches and injections of sustained-release progestin (starting at least 4 weeks before administration of the IMP), double-barrier method: condom or female condom (diaphragm or cervical/vaginal condom) plus spermicide, intrauterine device (IUD), intrauterine system, implant or vaginal ring (in place at least 4 weeks before administration of the IMP) or male partner sterilization (vasectomy with documentation of azoospermia) prior to inclusion of the woman in the trial if he is the woman's only sexual partner.
- •Active congestive heart failure class 2 or higher on the New York Heart Association (NYHA) scale.
- •Unstable angina (angina symptoms at rest), new-onset angina (having appeared in the past 3 months) or acute myocardial infarction that has occurred in the 6 months prior to starting with the study medication.
- •Cardiac arrhythmias that require anti-arrhythmic therapy (only beta blockers and digoxin would be allowed as concomitant medication for these patients).
- •Uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 90 mmHg) despite proper medical management.
- •Patients with phaeochromocytoma.
- •Pleural effusion or ascites that cause breathing difficulties (dyspnoea of grade ≥2 of the CTC).
- •Accidents (including transient ischaemic attacks), deep vein thrombosis or pulmonary thromboembolism that have occurred in the 6 months prior to starting with the study medication.
- •Active infection > grade 2 based on the NCI CTC, v. 4.
- •Human immunodeficiency virus (HIV) infection.
- •Active hepatitis B or C, or hepatitis B or C infection that requires treatment with antiviral drugs.
- •Patients with severe mental disorders that require medication.
- •Presence or history of brain metastases or meningeal tumours.
- •History of organ transplants.
- •Patients with evidence or history of bleeding diathesis. Any bleeding or bleeding event > Common Toxicity Criteria for Adverse Effects (CTCAE) grade 3 in the 4 weeks prior to starting with the study medication.
- •Presence of unhealed wounds, ulcers or bone fractures.
- •Kidney failure requiring haemodialysis or peritoneal dialysis.
- •Dehydration based on NCI CTC criteria, version 4, of >
- •Substance abuse or a history of medical, social or psychological conditions that may interfere with study participation or compliance with the efficacy and safety assessments planned in the study.
- •Known hypersensitivity to regorafenib or any of its excipients.
- •Presence of any disease or medical condition that might interfere with patient safety or may compromise treatment compliance with it.
- •Interstitial lung disease with signs and symptoms present at the time of signing the informed consent.
- •Patients who are unable to swallow oral medication.
- •Persistent proteinuria > grade 3 based on the NCI CTC, version 4.0 (> 3.5 g/24 hours).
- •Intestinal malabsorption syndrome.
- •Close personal relationship with the research staff, such as family members of the investigator or dependents (e.g. employees or students of the research centre).
- •Unresolved toxicity grade > 1 based on the NCI CTC, version 4.0 (except alopecia), related to any previous therapy or procedure.
研究组 & 干预措施
Regorafenib
Experimental
Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks,followed by one week of rest, according to the 3/1 regimen.
干预措施: Regorafenib (Drug)
结局指标
主要结局
Progression-free survival rate at 6 months
时间窗: 6 months
次要结局
- Objective response rate(30 months)
- Disease control rate(30 months)
- Time to response(30 months)
- Time to progression(30 months)
- Response duration(30 months)
- Progression-free survival(30 months)
- Time to treatment failure(30 months)
- Duration of stable disease(30 months)
- Overall survival(30 months)
- Incidence and severity of Adverse Events (NCI CTC, version 4.0)(30 months)
- Changes in laboratory values (transaminases, bilirubin, lactate dehydrogenase (LDH), anaemia,neutropenia and thrombocytopenia)(30 months)
- Change in vital signs (weight loss and hypertension)(30 months)
- Incidence of dose adjustments and compliance(30 months)
- Incidence of concomitant medication(30 months)
- Changes in ECOG performance status over time from baseline(30 months)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus BevacizumabMetastatic DiseaseColorectal NeoplasmsNCT02175654Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)15
进行中（未招募）
1 期
Regorafenib as a single agent for treatment of patients with metastatic colorectal cancer (MCRC) who are not candidates for polychemotherapyEUCTR2013-000236-94-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)
已完成
2 期
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal TumorGastrointestinal Stromal TumorNCT01068769Suzanne George, MD34
已完成
2 期
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With RegorafenibColorectal NeoplasmsNCT01289821Bayer54
进行中（未招募）
1 期
Study of Regorafenib drug for the treatment of patients with metastatic colorectal cancer (mCRC) with any RAS or BRAF gen mutation previously treated with FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) plus bevacizumabmetastatic colorectal cancerMedDRA version: 16.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2014-000703-26-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)